The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents, IV: the mechanisms involved in inhibiting cell-cycle progression
- 1 August 2001
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 98 (3), 842-850
- https://doi.org/10.1182/blood.v98.3.842
Abstract
Some chelators of the pyridoxal isonicotinoyl hydrazone class have antiproliferative activity that is far greater than desferrioxamine (DFO). In this study, DFO was compared with one of the most active chelators (311) on the expression of molecules that play key roles in cell-cycle control. This was vital for understanding the role of iron (Fe) in cell-cycle progression and for designing chelators to treat cancer. Incubating cells with DFO, and especially 311, resulted in a decrease in the hyperphosphorylated form of the retinoblastoma susceptibility gene product (pRb). Chelators also decreased cyclins D1, D2, and D3, which bind with cyclin-dependent kinase 4 (cdk4) to phosphorylate pRb. The levels of cdk2 also decreased after incubation with DFO, and especially 311, which may be important for explaining the decrease in hyperphosphorylated pRb. Cyclins A and B1 were also decreased after incubation with 311 and, to a lesser extent, DFO. In contrast, cyclin E levels increased. These effects were prevented by presaturating the chelators with Fe. In contrast to DFO and 311, the ribonucleotide reductase inhibitor hydroxyurea increased the expression of all cyclins. Hence, the effect of chelators on cyclin expression was not due to their ability to inhibit ribonucleotide reductase. Although chelators induced a marked increase in WAF1 and GADD45 mRNA transcripts, there was no appreciable increase in their protein levels. Failure to translate these cell-cycle inhibitors may contribute to dysregulation of the cell cycle after exposure to chelators.Keywords
This publication has 58 references indexed in Scilit:
- Iron Chelators Inhibit the Growth and Induce the Apoptosis of Kaposi's Sarcoma Cells and of their Putative Endothelial PrecursorsJournal of Investigative Dermatology, 2000
- p53-Independent Activation of the gadd45 Promoter by Δ12-Prostaglandin J2Biochemical and Biophysical Research Communications, 1998
- Analogues of Pyridoxal Isonicotinoyl Hydrazone (PIH) as Potential Iron Chelators for the Treatment of NeoplasiaLeukemia & Lymphoma, 1998
- Potential of iron chelators as effective antiproliferative agentsCanadian Journal of Physiology and Pharmacology, 1997
- Role of Deferoxamine in Tumor TherapyActa Haematologica, 1996
- Deferoxamine followed by cyclophosphamide, etoposide, carboplatin, thiotepa, induction regimen in advanced neuroblastoma: Preliminary resultsEuropean Journal Of Cancer, 1995
- WAF1, a potential mediator of p53 tumor suppressionCell, 1993
- The effect of various chelating agents on the mobilization of iron from reticulocytes in the presence and absence of pyridoxal isonicotinoyl hydrazoneBiochimica et Biophysica Acta (BBA) - General Subjects, 1984
- Antineoplastic and antiherpetic activity of spermidine catecholamide iron chelatorsBiochemical and Biophysical Research Communications, 1984
- Continual presence of oxygen and iron required for mammalian ribonucleotide reduction: Possible regulation mechanismBiochemical and Biophysical Research Communications, 1983